Clinical trials
Hepatic Impairment clinical trials
Below are recruiting hepatic impairment clinical trials, each written for real people, not researchers. We’re tracking 36 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07023354RecruitingPhase 1
Study of BI 1291583 in people with and without liver problems
This trial tests how a new medicine, BI 1291583, enters the blood in people who have different levels of liver function (from normal to mild, moderate, or severe liver problems). It helps doctors understand if the dose needs to be adjusted for liver health.
Rialto, CaliforniaAges 18–80 - NCT07269301RecruitingPhase 1
Liver function and study drug processing
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
Lake Forest, CaliforniaAges 18–74 - NCT07282093RecruitingPhase 1
Olverembatinib in people with liver problems
This trial tests how a drug called olverembatinib is processed by the body in people with different levels of liver impairment. It looks at how the liver condition affects the drug levels and safety, which may help find the right dose.
Suzhou, JiangsuAges 18–75 - NCT06825559RecruitingPhase 1
Saroglitazar safety in moderate liver impairment from cholestatic disease
This trial tests how the body processes saroglitazar in people with moderate liver impairment caused by cholestatic liver disease. The goal is to ensure the drug is safe and dosed correctly for this group.
Indianapolis, IndianaAges 18–80 - NCT04953910RecruitingPhase 1
Oral decitabine for cancers with liver problems
This Phase 1 trial studies how a pill form of decitabine/cedazuridine behaves in the body and how safe it is for people whose livers don’t work normally. It may help doctors better understand dosing and safety in patients with hepatic impairment.
Houston, TexasAges 18 years+ - NCT07152288RecruitingPhase 1
Study of HSK39297 in people with liver problems
This trial tests how a new drug, HSK39297, works in people with mild to moderate liver impairment (Child-Pugh A or B). It compares them to healthy volunteers to see how the liver affects the drug's safety and how the body processes it.
BeijingAges 18–70 - NCT07358546RecruitingPhase 1
Test of efimosfermin alfa in adults with liver problems
This trial is for adults with liver cirrhosis (scarring) who have moderate to severe liver impairment. It studies how the body handles a new medicine called efimosfermin alfa, to see if it could be a safe treatment option. You may be able to join if your liver function is stable and you fall into a specific Child-Pugh class.
Rialto, CaliforniaAges 18–70 - NCT07480824RecruitingPhase 1
Liver function and safety of TQ05105 tablet
This study tests how a tablet called TQ05105 is processed in people with different levels of liver function. It helps doctors understand the right dose for patients with liver problems.
Luoyang, HenanAges 18–75 - NCT07486102RecruitingPhase 1
Study of BI 3000202 in people with and without liver problems
This study tests how a new medicine, BI 3000202, is absorbed into the blood. It includes people with different levels of liver function (normal, mild, moderate, or severe) to see if liver problems affect how the medicine works.
San Antonio, TexasAges 18–80 - NCT07165002RecruitingPhase 1
Study of LY3537031 in people with and without liver problems
This trial tests how a new medicine, LY3537031, moves through the body and how safe it is for people with different levels of liver function. It includes people with normal livers and those with mild, moderate, or severe liver impairment.
KistarcsaAges 18–85 - NCT07006688RecruitingPhase 1
Ivosidenib for IDH1-mutated cancers with liver or kidney issues
This trial tests an oral drug (ivosidenib) for people with IDH1-mutated cancers who also have liver or kidney problems. It aims to find the right dose and see how safe and effective it is for these patients.
Atlanta, GeorgiaAges 18 years+ - NCT07342881RecruitingPhase 1
Single dose study of pevifoscorvir in people with kidney impairment
This study tests how a single dose of the study drug, pevifoscorvir, is processed in people with different levels of kidney function. It helps understand if the dose needs to be adjusted for people with kidney problems.
Orlando, FloridaAges 18–75
Hear when a new Hepatic Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatic impairment?
- Yes. Clin2 currently lists 36 recruiting hepatic impairment studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatic impairment trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatic impairment trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.